GlassScriptPhysician profile
Michael C Elliott
NPI 1306312822
$2,300.97
in general payments reported to CMS, 2019-2025
17 companies · $816 in 2025
The $816 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $708 · 2024: $778 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282 · Debt Forgiveness: $18.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.17 |
| Debt Forgiveness | $18.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $718.06 | 2023-2025 | |
| Lilly USA, LLC | $310.72 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $267.19 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $254.25 | 2023-2025 | |
| Pfizer INC. | $233.32 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $87.21 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $84.53 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $78.22 | 2023-2025 | Farxiga |
| Idorsia Pharmaceuticals US INC | $59.27 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $39.15 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Corcept Therapeutics | $35.29 | 2025 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $31.71 | 2023-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $31.03 | 2023 | Seglentis, Livalo |
| Baxter Healthcare | $18.80 | 2024 | |
| Xeris Pharmaceuticals, INC. | $17.63 | 2024 | Gvoke Hypopen |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.49 | 2024 | Evenity, Prolia |
| Dexcom, INC. | $17.10 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.